# Agape ATP Corp: Form 10-Q for the period ended Dec 31, 2018

- Company: [Agape ATP Corp](/companies/atpc.md) (CIK 1713210)
- Form: 10-Q
- Filed: 2019-02-15
- Accepted by EDGAR: Feb 15, 2019, 09:38 ET
- Period: 2018-12-31
- Accession: 0001493152-19-002158
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1713210/000149315219002158/form10-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1713210/000149315219002158/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-10-01 to 2018-12-31 | $269.9k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2018-10-01 to 2018-12-31 | $240.9k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2018-07-01 to 2018-12-31 | $619.4k | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2018-10-01 to 2018-12-31 | $29.0k | us-gaap:GrossProfit |
| Gross profit | 6 months, 2018-07-01 to 2018-12-31 | $65.9k | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2018-10-01 to 2018-12-31 | $24.5k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2018-07-01 to 2018-12-31 | $63.1k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Income tax | 3 months, 2018-10-01 to 2018-12-31 | $3.3k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2018-07-01 to 2018-12-31 | $7.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-10-01 to 2018-12-31 | −$6.6k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2018-07-01 to 2018-12-31 | −$142.4k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-10-01 to 2018-12-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2018-07-01 to 2018-12-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2018-07-01 to 2018-12-31 | −$77.3k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2018-12-31 | $3.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-12-31 | $4.0m | us-gaap:AssetsCurrent |
| Total assets | at 2018-12-31 | $5.2m | us-gaap:Assets |
| Current liabilities | at 2018-12-31 | $241.8k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-12-31 | $241.8k | us-gaap:Liabilities |
| Shareholders' equity | at 2018-12-31 | $5.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 7,285 characters.

*The information contained in this quarter report on Form 10-Q is intended to update the information contained in our Form 10-K, dated September 27, 2018, for the year ended June 30, 2018 and presumes that readers have access to, and will have read, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other information contained in such Form 10-K. The following discussion and analysis also should be read together with our consolidated financial statements and the notes to the consolidated financial statements included elsewhere in this Form 10-Q.*

*The following discussion contains certain statements that may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements appear in a number of places in this Report, including, without limitation, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements are not guarantees of future performance and involve risks, uncertainties and requirements that are difficult to predict or are beyond our control. Forward-looking statements speak only as of the date of this quarterly report. You should not put undue reliance on any forward-looking statements. We strongly encourage investors to carefully read the factors described in our Form S-1 Amendment No.2, dated October 26, 2017, in the section entitled “Risk Factors” for a description of certain risks that could, among other things, cause actual results to differ from these forward-looking statements. We assume no responsibility to update the forward-looking statements contained in this transition report on Form 10-Q. The following should also be read in conjunction with the unaudited Condensed Consolidated Financial Statements and notes thereto that appear elsewhere in this report.*

### Company Overview

Agape ATP Corporation., a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016. Agape ATP Corporation is a company that operates through its wholly owned subsidiary, Agape ATP Corporation, a company incorporated in Labuan, Malaysia. Our wholly owned subsidiary, Agape ATP Corporation owns 100% of Agape ATP International Holding Limited, the operating Hong Kong company.

Agape ATP Corporation is a company which plans to develop and provide health solution advisory services to our future clients. We will, at least initially, primarily focus our efforts on attracting customers in Malaysia. Our advisory services will center around the “ATP Zeta Health Program”, which is a health program designed to assist in the elimination of various diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition, and advice from skilled dieticians.

At its core, the ATP Zeta Super Health Program is focused upon biological energy, Adenosine Triphosphate (ATP), at the cellular level. The stimulation of ATP production at the cellular level can increase the metabolism and service to promote and maintain normal and healthy functioning of the body’s systems. Our program emphasizes nutrient absorption through the membrane ion channel to provide complete and balanced nutrients to improve cell health. Thus, ATP Zeta Super Health Program provides ionized and high zeta potential (high bioavailability) nutrients to enhance the absorption at the cellular level.

### Results of Operation

### For the three months ended December 31, 2018 and 2017

### Revenues

For three months ended December 31, 2018, the Company has generated revenue of $269,921. The revenue mainly derived from the sale of healthy food products. For three month ended December 31, 2017, the Company has generated no revenue.

### Net Loss

Our net loss for three months ended December 31, 2018 were $6,580, while for three months ended December 31, 2017 were $123,978. We attribute the net loss in 2018 due to loss of investee company while in 2017 due to zero revenue.

### For the six months ended December 31, 2018 and 2017

### Revenues

For six months ended December 31, 2018 and 2017, the Company has generated revenue of $685,288 and $489,499 respectively. The revenue mainly derived from the sale of healthy food products.

Our gross profits for the six months ended December 31, 2018 were $65,933, which is more than $45,829 for six months ended December 31, 2017. We attribute the increase in revenue and gross profit to increase of market exposure and the introduction of other new products in 2018. We believe that in order to retain and maintain more customers in the future we must increase our marketing efforts and or develop new products.

### Net Loss

Our net loss for six months ended December 31, 2018 were $142,446, while for six months ended December 31, 2017 were $178,678. We attribute the net loss decreased due to lower selling, administrative and general expenses and the increasing revenue which resulted in higher gross profit.

### Liquidity and Capital Resources

As at December 31, 2018, we had working capital surplus of $3,721,139 consisting of cash and cash equivalents of $3,452,917 as compared to working capital surplus of $3,766,446 and cash and cash equivalents of $3,531,255 as of June 30, 2018.

### Cash Provided by/Used in Operating Activities

For the six months ended December 31, 2018, net cash used in operating activities was $77,337. The operating cash flow performance primarily reflects the deposits received from customer of the Company.

For the six months ended December 31, 2017, net cash used in operating activities was $892,833. The operating cash flow performance primarily reflects the prepayment and deposits as well as increasing account receivables of the Company.

### Cash Provided by/Used in Financing Activities

For the six months ended December 31, 2018, net cash used in financing activities was $1,000 for the additional of investment in financial asset.

For the six months ended December 31, 2017, net cash provided by financing activities was $434,500 which is the proceed from the issuance of stock.

### Cash Provided by/Used in Investing Activities

For the six months ended December 31, 2018 and 2017, there is no net cash provided by or used in investing activities.

### Credit Facilities

We do not have any credit facilities or other access to bank credit.

### Off-balance Sheet Arrangements

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders as of December 31, 2018.

### Recent Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

## Market risk

As filed, 147 characters.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

## Controls and procedures

As filed, 1,708 characters.

### Evaluation of Disclosure Controls and Procedures:

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of December 31, 2018. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2018, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of December 31, 2018, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

### Changes in Internal Control over Financial Reporting:

There were no changes in our internal control over financial reporting during the quarter ended December 31, 2018, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 163 characters.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

Filed Feb 15, 2019.
Source: SEC EDGAR, the filing index for accession 0001493152-19-002158. Last ingested by Listed: Nov 6, 2026, 16:53 ET. No prices; not investment advice.
